Last reviewed · How we verify
Mycophenolate Mofetil (MMF)
Mycophenolate Mofetil (MMF) is a Inosine monophosphate dehydrogenase (IMPDH) inhibitor Small molecule drug developed by ITB-Med LLC. It is currently FDA-approved for Prevention of organ rejection in renal, cardiac, and hepatic transplant recipients, Active lupus nephritis, Autoimmune hemolytic anemia. Also known as: Cellcept, CellCept, MMF, Cellcept®.
Mycophenolate mofetil is a prodrug that inhibits inosine monophosphate dehydrogenase (IMPDH), selectively suppressing T and B lymphocyte proliferation to prevent organ rejection and treat autoimmune diseases.
Mycophenolate Mofetil (MMF) is a small molecule inhibitor of inosine-5'-monophosphate dehydrogenase (IMPDH), a type of enzyme. It is used to treat various conditions, including Neuromyelitis Optica Spectrum Disorder (NMOSD), BK Virus Nephropathy After Kidney Transplantation, Kidney Transplant Infection, Leukemia, and Lymphoma.
At a glance
| Generic name | Mycophenolate Mofetil (MMF) |
|---|---|
| Also known as | Cellcept, CellCept, MMF, Cellcept®, Mycophenolate mofetil |
| Sponsor | ITB-Med LLC |
| Drug class | Inosine monophosphate dehydrogenase (IMPDH) inhibitor |
| Target | IMPDH type II |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Mechanism of action
MMF is rapidly converted to mycophenolic acid (MPA), its active metabolite, which preferentially inhibits IMPDH type II, an enzyme critical for guanosine nucleotide synthesis in lymphocytes. This selective depletion of guanosine nucleotides suppresses T and B cell proliferation while having minimal effects on other cell types. The result is potent immunosuppression useful in preventing allograft rejection and managing autoimmune conditions.
Approved indications
- Prevention of organ rejection in renal, cardiac, and hepatic transplant recipients
- Active lupus nephritis
- Autoimmune hemolytic anemia
- Certain vasculitides and other autoimmune conditions
Common side effects
- Gastrointestinal disturbances (diarrhea, nausea, vomiting, abdominal pain)
- Leukopenia
- Anemia
- Infection (bacterial, viral, fungal)
- Headache
- Tremor
- Hypertension
- Hyperglycemia
Key clinical trials
- Pilot Trial of Allogeneic Blood or Marrow Transplantation for Primary Immunodeficiencies (PHASE2)
- Belimumab and Rituximab Combination Therapy for the Treatment of Diffuse Cutaneous Systemic Sclerosis (PHASE2)
- Radiation- and Alkylator-free Bone Marrow Transplantation Regimen for Patients With Dyskeratosis Congenita (PHASE2)
- Tocilizumab in Lung Transplantation (PHASE2)
- A Study to Investigate the Efficacy and Safety of Frexalimab Versus Tacrolimus in Adults Undergoing Kidney Transplantation (PHASE2, PHASE3)
- MT2025-35 Allogeneic Hematopoietic Stem Cell Transplantation Using Reduced Intensity Conditioning Treosulfan and Fludarabine, With Post-Transplant Cytoxan (PTCy) for the Treatment of Hematological Diseases (PHASE2)
- Therapeutic Drug Monitoring of Mycophenolate Mofetil in Lupus Nephritis (NA)
- Upfront Autologous HSCT Versus Immunosuppression in Early Diffuse Cutaneous Systemic Sclerosis (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Mycophenolate Mofetil (MMF) CI brief — competitive landscape report
- Mycophenolate Mofetil (MMF) updates RSS · CI watch RSS
- ITB-Med LLC portfolio CI
Frequently asked questions about Mycophenolate Mofetil (MMF)
What is Mycophenolate Mofetil (MMF)?
How does Mycophenolate Mofetil (MMF) work?
What is Mycophenolate Mofetil (MMF) used for?
Who makes Mycophenolate Mofetil (MMF)?
Is Mycophenolate Mofetil (MMF) also known as anything else?
What drug class is Mycophenolate Mofetil (MMF) in?
What development phase is Mycophenolate Mofetil (MMF) in?
What are the side effects of Mycophenolate Mofetil (MMF)?
What does Mycophenolate Mofetil (MMF) target?
Related
- Drug class: All Inosine monophosphate dehydrogenase (IMPDH) inhibitor drugs
- Target: All drugs targeting IMPDH type II
- Manufacturer: ITB-Med LLC — full pipeline
- Therapeutic area: All drugs in Immunology
- Indication: Drugs for Prevention of organ rejection in renal, cardiac, and hepatic transplant recipients
- Indication: Drugs for Active lupus nephritis
- Indication: Drugs for Autoimmune hemolytic anemia
- Also known as: Cellcept, CellCept, MMF, Cellcept®, Mycophenolate mofetil
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing